(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 June 2013 (27.06.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/093762 A1

(51) International Patent Classification:
C07K 16/18 (2006.01)

(21) International Application Number:
PCT/IB2012/057394

(22) International Filing Date:
17 December 2012 (17.12.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/578,458 21 December 2011 (21.12.2011) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors: **BRANNETTI, Barbara**; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **GHOSH, Joy**; Novartis Institutes for Biomedical Research, Inc., 500 Technology Square, Cambridge, MA 02139 (US). **JAEGER, Ute**; Morphosys AG, Lena-Christ-Strasse 48, 82152 Planegg (DE). **JOHNSON, Leslie**; Novartis Institutes for Biomedical Research, Inc., 500 Technology Square, Cambridge, MA 02139 (US). **KIM, Yong-In**; Novartis Institutes for Biomedical Research, Inc., 500 Technology Square, Cambridge, MA 02139 (US). **KUNZ, Christian Carsten Silvester**; Morphosys AG, Lena-Christ-Strasse 48, 82152 Planegg (DE). **ROGUSKA, Michael**; Novartis Institutes for Biomedical Research, Inc., 500 Technology Square, Cambridge, MA 02139 (US). **SPLAWSKI, Igor**; Novartis Institutes for Biomedical Research, Inc., 100 Technology Square, Cambridge, MA 02139 (US).

(74) Agent: **BEAUDET, Matthew**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) **Title**: COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING FACTOR P

FIG 1A




FIG 1B





FIG 1C



(57) **Abstract**: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti- Factor P antibodies with antibodies or antigen binding fragments thereof that bind to compelement component 5 (C5).

WO 2013/093762 A1